Influenza Vaccine Safety and Effectiveness in Healthcare Providers
The overall objective of this study is to provide ongoing assessment of the safety and effectiveness of seasonal and pandemic H1N1 vaccines in the prevention of ILI (influenza like illness), ILI-associated work absenteeism, and laboratory-confirmed influenza in a cohort of Canadian HCP (Health care providers). Given the uncertainties around the timing of the provision of seasonal influenza immunization to HCP for the 2009/10 influenza season, this study will focus on evaluation of safety and effectiveness of pandemic influenza immunization in Year 1 and evaluation of all recommended influenza vaccines in Years 2 and 3.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Monitoring Seasonal and Pandemic Vaccine Safety and Effectiveness in Healthcare Providers:A Prospective Cohort Study|
- Assessment of the safety and tolerability of seasonal and pandemic influenza vaccine among a cohort of HCP [ Time Frame: October to April each year ] [ Designated as safety issue: Yes ]Health care providers will receive automated email reminders with a link to report any changes in their health within 4 weeks of vaccination.
- To validate published ILI case definitions in a cohort of HCP [ Time Frame: October to April each year ] [ Designated as safety issue: No ]A cohort of HCP will be asked via an automated email to report the presence of an upper respiratory illness and to self collect a nasal swab to be tested for influenza.
|Study Start Date:||October 2009|
|Estimated Study Completion Date:||June 2012|
|Estimated Primary Completion Date:||April 2012 (Final data collection date for primary outcome measure)|
Participants in Year 1 (2009/10) will be recruited beginning Oct. 1 through the end of the pandemic H1N1 influenza immunization campaign.
Participants will be followed from the day of vaccination until the end of the influenza season approximately Oct-April for each season.
At the initial visit, participants will have 1 tube of blood (10cc) collected at the time of enrolment to determine baseline antibody titres against pandemic H1N1 and the influenza strains in the past and current year's seasonal influenza vaccines.
Participants will receive automated email reminders with links to follow-up web-based questionnaires at weekly intervals following the completion of the baseline survey and until the end of the influenza season.
If a participant reports a respiratory illness, they will receive a follow-up questionnaire asking details of the illness including the occurrence of respiratory illness and associated symptoms, contact with patients or household members that had respiratory illness, respiratory symptom-related healthcare utilization, prescription or over-the-counter products used for treatment of the respiratory illness, and number of days of work missed due to respiratory illness or worked with symptomatic respiratory tract infection. An email will be sent to each participant every Monday morning during the season reminding the participant to complete their weekly diary and report and send in their nasal swab if they have symptoms of an acute respiratory illness.
At the initial visit participants will be taught how to collect their nasal swab and will practice doing their own swab in the presence of the study nurse/research associate. Participants will be instructed to collect a nasal swab and return the swabs as soon as possible after onset of ILI or respiratory illness (target < 48h after onset). Participants will be asked to collect the swab if they develop symptoms compatible with a viral respiratory tract infection (fever without an apparent source OR new symptoms with at least 2 of the following -cough, runny/stuffy nose, sneezing, sore/scratchy throat, hoarseness, malaise, myalgia, headache, fatigue OR one local symptom (runny/stuffy nose, sneezing, sore/scratchy throat, hoarseness, cough) plus one systemic symptom (fever, malaise, myalgia, headache, fatigue). If they prefer, a nasopharyngeal swab will be collected by a member of the study team as soon as possible after the onset of symptoms.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01282177
|Principal Investigator:||Shelly A McNeil, MD||Dalhousie University|
|Principal Investigator:||Allison McGeer, MD||Mount Sinai Hospital, New York|
|Principal Investigator:||Anne McCarthy, MD||The Ottawa Hospital|
|Principal Investigator:||Mark Loeb, MD||Hamilton Health Sciences Center|
|Principal Investigator:||Grant Stiver, MD||Vancouver General Hospital|
|Principal Investigator:||Brenda Coleman, MD||Mount Sinai Hospital, New York|